360 related articles for article (PubMed ID: 34029143)
1. Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome.
Ning L; Suleiman HY; Miner JH
Am J Physiol Renal Physiol; 2021 Jul; 321(1):F12-F25. PubMed ID: 34029143
[TBL] [Abstract][Full Text] [Related]
2. Synaptopodin Is Dispensable for Normal Podocyte Homeostasis but Is Protective in the Context of Acute Podocyte Injury.
Ning L; Suleiman HY; Miner JH
J Am Soc Nephrol; 2020 Dec; 31(12):2815-2832. PubMed ID: 32938649
[TBL] [Abstract][Full Text] [Related]
3. Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.
Steenhard BM; Vanacore R; Friedman D; Zelenchuk A; Stroganova L; Isom K; St John PL; Hudson BG; Abrahamson DR
PLoS One; 2012; 7(12):e50745. PubMed ID: 23236390
[TBL] [Abstract][Full Text] [Related]
4. Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner.
Asanuma K; Kim K; Oh J; Giardino L; Chabanis S; Faul C; Reiser J; Mundel P
J Clin Invest; 2005 May; 115(5):1188-98. PubMed ID: 15841212
[TBL] [Abstract][Full Text] [Related]
5. Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes.
Yanagida-Asanuma E; Asanuma K; Kim K; Donnelly M; Young Choi H; Hyung Chang J; Suetsugu S; Tomino Y; Takenawa T; Faul C; Mundel P
Am J Pathol; 2007 Aug; 171(2):415-27. PubMed ID: 17569780
[TBL] [Abstract][Full Text] [Related]
6. Pathogenicity of a Human Laminin
Funk SD; Bayer RH; Malone AF; McKee KK; Yurchenco PD; Miner JH
J Am Soc Nephrol; 2018 Mar; 29(3):949-960. PubMed ID: 29263159
[TBL] [Abstract][Full Text] [Related]
7. Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.
Ding F; Wickman L; Wang SQ; Zhang Y; Wang F; Afshinnia F; Hodgin J; Ding J; Wiggins RC
Kidney Int; 2017 Dec; 92(6):1515-1525. PubMed ID: 28754557
[TBL] [Abstract][Full Text] [Related]
8. The Accumulation of VEGFA in the Glomerular Basement Membrane and Its Relationship with Podocyte Injury and Proteinuria in Alport Syndrome.
Wang H; Yue Z; Wu J; Liu T; Mo Y; Jiang X; Sun L
PLoS One; 2015; 10(8):e0135648. PubMed ID: 26274923
[TBL] [Abstract][Full Text] [Related]
9. Ramipril therapy in integrin α1-null, autosomal recessive Alport mice triples lifespan: mechanistic clues from RNA-seq analysis.
Madison J; Wilhelm K; Meehan DT; Gratton MA; Vosik D; Samuelson G; Ott M; Fascianella J; Nelson N; Cosgrove D
J Pathol; 2024 Mar; 262(3):296-309. PubMed ID: 38129319
[TBL] [Abstract][Full Text] [Related]
10. Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome.
LeBleu VS; Kanasaki K; Lovisa S; Alge JL; Kim J; Chen Y; Teng Y; Gerami-Naini B; Sugimoto H; Kato N; Revuelta I; Grau N; Sleeman JP; Taduri G; Kizu A; Rafii S; Hochedlinger K; Quaggin SE; Kalluri R
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38561223
[TBL] [Abstract][Full Text] [Related]
11. Regulation of podocyte BK(Ca) channels by synaptopodin, Rho, and actin microfilaments.
Kim EY; Suh JM; Chiu YH; Dryer SE
Am J Physiol Renal Physiol; 2010 Sep; 299(3):F594-604. PubMed ID: 20630939
[TBL] [Abstract][Full Text] [Related]
12. Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases.
Mitrofanova A; Fontanella A; Tolerico M; Mallela S; Molina David J; Zuo Y; Boulina M; Kim JJ; Santos J; Ge M; Sloan A; Issa W; Gurumani M; Pressly J; Ito M; Kretzler M; Eddy S; Nelson R; Merscher S; Burke G; Fornoni A
J Am Soc Nephrol; 2022 Dec; 33(12):2153-2173. PubMed ID: 36198430
[TBL] [Abstract][Full Text] [Related]
13. Endothelial cell-specific collagen type IV-α
Funk SD; Bayer RH; Miner JH
Am J Physiol Renal Physiol; 2019 May; 316(5):F830-F837. PubMed ID: 30724107
[TBL] [Abstract][Full Text] [Related]
14. Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects.
Abrahamson DR; Isom K; Roach E; Stroganova L; Zelenchuk A; Miner JH; St John PL
J Am Soc Nephrol; 2007 Sep; 18(9):2465-72. PubMed ID: 17699809
[TBL] [Abstract][Full Text] [Related]
15. Laminin-1 reexpression in Alport mouse glomerular basement membranes.
Abrahamson DR; Prettyman AC; Robert B; St John PL
Kidney Int; 2003 Mar; 63(3):826-34. PubMed ID: 12631063
[TBL] [Abstract][Full Text] [Related]
16. Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease.
Meehan DT; Delimont D; Cheung L; Zallocchi M; Sansom SC; Holzclaw JD; Rao V; Cosgrove D
Kidney Int; 2009 Nov; 76(9):968-76. PubMed ID: 19710627
[TBL] [Abstract][Full Text] [Related]
17. Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases.
Sever S; Schiffer M
Kidney Int; 2018 Jun; 93(6):1298-1307. PubMed ID: 29678354
[TBL] [Abstract][Full Text] [Related]
18. Effect of disease progression on the podocyte cell cycle in Alport Syndrome.
Frank CN; Hou X; Petrosyan A; Villani V; Zhao R; Hansen JR; Clair G; Salem F; De Filippo RE; Cravedi P; Lemley KV; Perin L
Kidney Int; 2022 Jan; 101(1):106-118. PubMed ID: 34562503
[TBL] [Abstract][Full Text] [Related]
19. COL4A3/COL4A4 mutations link familial hematuria and focal segmental glomerulosclerosis. glomerular epithelium destruction via basement membrane thinning?
Voskarides K; Pierides A; Deltas C
Connect Tissue Res; 2008; 49(3):283-8. PubMed ID: 18661361
[TBL] [Abstract][Full Text] [Related]
20. α1β1 integrin/Rac1-dependent mesangial invasion of glomerular capillaries in Alport syndrome.
Zallocchi M; Johnson BM; Meehan DT; Delimont D; Cosgrove D
Am J Pathol; 2013 Oct; 183(4):1269-1280. PubMed ID: 23911822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
